Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine TumorWei, Xiao, MD*; Hain, Susanne, MD†; Hartmann, Lynn, MD*; Hirzebruch, Stefan, MD*; Ahmadzadehfar, Hojjat, MD, MSc*Clinical Nuclear Medicine: June 2019 - Volume 44 - Issue 6 - p 480–482 doi: 10.1097/RLU.0000000000002519 Interesting Images Buy Abstract Author InformationAuthors Article MetricsMetrics A 68-year-old man with a metastatic neuroendocrine tumor with unknown primary was found to have partially dedifferentiated metastases according to 18F-FDG uptake. He received 3 cycles of radiopeptide therapy using [177Lu]Lutetium-DOTATATE combined with temozolomide. Before this treatment, the patient had already undergone a series of therapies, including biotherapy, everolimus, 5 cycles of radiopeptide therapies, radiotherapy, and bone-protecting therapy with bisphosphonate and receptor activator of NF-κB ligand, each of which temporarily stalled the progress of the disease. After combined treatment with radiopeptide therapy and temozolomide, the patient showed a very good response in all tumor lesions, including the FDG-positive ones. From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn; and †Marien Gesellschaft, Siegen, Germany. Received for publication December 28, 2018; revision accepted January 21, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Hojjat Ahmadzadehfar, MD, MSc, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: firstname.lastname@example.org or email@example.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.